INTRODUCTION
============

The clinical presentation of antiphospholipid syndrome may be heterogeneous and multiple organs can be involved. A minority of patients may have clinical signs suggestive of antiphospholipid syndrome but also persistent negative levels of antibodies (cardiolipin antibodies, anti-β2 glycoprotein 1 antibodies and lupus anticoagulant). Ongoing research has revealed the existence of non-criteria antibodies which may be relevant for the diagnosis of antiphospholipid syndrome and which could be included in the classification criteria for the disease^\[[@b1-1180-1-9165-1-10-20190918]\]^. In this case report, we evaluate anti-vimentin/cardiolipin antibodies (AVA/CL), which, as demonstrated by Ortona et al.^\[[@b2-1180-1-9165-1-10-20190918]\]^, mediate activation of the TLR4/IRAK/Nf-kB molecular pathway leading to the release of pro-inflammatory and procoagulant factors by endothelial cells.

AVA/CL antibodies are an intriguing candidate because they are common in seronegative antiphospholipid syndrome (SN-APS) and also seem to exert a pro-thrombotic effect^\[[@b3-1180-1-9165-1-10-20190918]\]^. Indeed, antibodies against AVA/CL complex showed a prothrombotic effect and may be involved in arterial thrombosis by inducing platelet and coagulation cascade activation, such as demonstrated in a study conducted on cardiac allografts^\[[@b4-1180-1-9165-1-10-20190918]\]^.

CASE REPORT
===========

A 69-year-old male patient was admitted to the Emergency Department of Umberto I University Hospital Rome for progressive asthenia, abdominal pain with constipation and confusion. His medical history was characterized by ischaemic heart disease treated with triple bypass surgery, recent ischaemic stroke (about 2 months previously), arterial hypertension and benign prostatic hyperplasia. The patient was on chronic medication with aspirin 100 mg/daily, carvedilol 25 mg/daily, atorvastatin 20 mg/daily, dutasteride 0.5 mg/daily and tamsulosin 0.4 mg/daily.

On physical examination, the patient appeared alert and oriented in time and space and did not show any focal neurological defects.

During his stay in the Emergency Department, the patient experienced epigastric pain and profuse sweating. Electrocardiography showed ST segment elevation in all precordial derivations. High-sensitive troponin T was raised at 0.238 μg/l (normal value \<0.014 μg/l). Therefore, ASA 250 mg, ticagrelor 180 mg and fondaparinux 2.5 mg were administered; percutaneous transluminal coronary angiography was then performed through the left femoral artery, but there were no acute differences from previous angiographic examinations and no endovascular procedures were performed.

Concomitantly with percutaneous transluminal coronary angiography, arterial blood gas analysis from the left brachial artery was performed. After a few hours, the left hand became pale and cold and neither an ulnar nor radial pulse could be detected. Ultrasound and computed tomography angiography (CTA) demonstrated obstruction of the left circumflex humeral artery. The patient was started on unfractionated heparin infusion and aspirin was discontinued. He was then moved from the Emergency Department to the Internal Medicine Ward, where unfractionated heparin infusion was discontinued and enoxaparin 4,000 IU bid was started. Laboratory findings are reported in [Table 1](#t1-1180-1-9165-1-10-20190918){ref-type="table"}.

During the hospital stay, a pulsatile painless mass was noted in the left femoral area. Arteriography revealed a femoral pseudoaneurysm, which was successfully treated with arteriorrhaphy.

The patient also complained of a painful lower right limb, which appeared pale on physical examination, and no arterial pulse was detectable. CTA demonstrated a thrombotic formation in the right superficial femoral artery extending to the right common femoral artery. This second ischaemic event was effectively treated with thromboendarterectomy.

We considered possible aetiologies for these recurrent arterial thrombotic events. We investigated the panel of autoantibodies listed in [Table 1](#t1-1180-1-9165-1-10-20190918){ref-type="table"}. We found that all conventional autoantibodies required for the diagnosis of antiphospholipid syndrome were negative. We also tested the patient for the most common inherited causes of thrombophilia, such as protein C, protein S, antithrombin III, activated protein C resistance, factor V Leiden, and Factor gene mutation, which were all within normal ranges.

Thus, a diagnosis of SN-APS was made. Further investigation with plasma assay of AVA/CL showed above-normal values ([Table 1](#t1-1180-1-9165-1-10-20190918){ref-type="table"}).

At discharge the patient was prescribed vitamin K antagonists (INR range 2--3) and aspirin 100 mg/daily was restarted. Other medications were unchanged. The patient is undergoing regular follow-up visits and no other thrombotic events have occurred.

This case report describes SN-APS with multiple recurrent arterial thrombosis in a patient without the typical criteria for antiphospholipid syndrome.

DISCUSSION
==========

Here, we report the case of a patient who developed multiple arterial thrombosis over a very short period in various vascular districts. We made a diagnosis of SN-APS by exclusion, as no other evident cause of arterial thrombosis was found, and all antibodies required for a diagnosis of antiphospholipid syndrome were negative. Interestingly, the positivity for AVA/CL persisted at 3 and 6 months after discharge, along with negativity for all other antibodies.

The role of AVA/CL in SN-APS has been investigated in only one previous study. Ortona et al.^\[[@b2-1180-1-9165-1-10-20190918]\]^ analyzed serum IgG AVA/CL antibodies detected by ELISA in 29 SN-APS patients, 40 patients with antiphospholipid syndrome, 30 patients with systemic lupus erythematosus, 30 patients with rheumatoid arthritis, and 32 healthy control patients. They found positivity for AVA/CL in almost all patients with antiphospholipid syndrome (92%), and also in a large proportion of SN-APS patients (55%). It was noteworthy that this positivity was persistent in almost all cases.

Anti-vimentin antibodies can be generated upon invasive endovascular procedures, which may represent a local injury to vascular homeostasis triggering an inflammatory response. Thus, in our patient, anti-vimentin antibody formation may have been facilitated by percutaneous transluminal coronary angiography, sampling for arterial blood gas analysis and arteriorrhaphy procedures.

Nevertheless, we cannot exclude the involvement of other autoantibodies not tested in the present study ([Table 1](#t1-1180-1-9165-1-10-20190918){ref-type="table"} shows a full list of suggested non-conventional antibodies in SN-APS).

All these findings suggest AVA/CL is a potential candidate as an additional diagnostic criterion for SN-APS^\[[@b5-1180-1-9165-1-10-20190918]\]^. However, there is not enough evidence to support its routine use in clinical practice, and its assessment should be reserved for patients with no other evident causes of thrombosis.

In conclusion, our case suggests that evaluation of AVA/CL may be helpful in patients with multiple arterial thrombosis who do not fulfil antiphospholipid syndrome criteria.
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###### 

Laboratory findings

                                                         Result      Normal Range
  ------------------------------------------------------ ----------- --------------------------
  *Creatinine*                                           *0.5*       *0.1--1.2 mg/dl*
  *High-sensitive troponin T*                            *0.025*     *\<0.014 μg/l*
  *Glutamic oxaloacetic transaminase (GOT)*              *13*        *8--38 IU/l*
  *Glutamic-pyruvic transaminase (GPT)*                  *9*         *12--41 IU/l*
  *Myoglobin*                                            *34*        *28--72 ng/ml*
  *Creatine phosphokinase (CPK)*                         *50*        *39--308 IU/l*
  *Haemoglobin (HGB)*                                    *14*        *13--17 g/dl*
  *White blood cell count (WBC)*                         *9,190*     *4,000--10,000/mm^3^*
  *Platelets*                                            *231,000*   *150,000--450,000/mm^3^*
  *International normalized ratio (INR)*                 *1.14*      *0.8--1.2*
  *Activated partial thromboplastin time (aPTT ratio)*   *0.99*      *0.8--1.2*
  *Fibrinogen*                                           *282*       *200--400 mg/dl*
  *C-reactive protein*                                   *\<0.1*     *\<0.5 mg/dl*

  -----------------------------------------------------------------------
  Autoantibodies                            Result        Normal Range
  ----------------------------------------- ------------- ---------------
  *Anti-nuclear antibodies (ANA)*           *Negative*\   *Negative*
                                            *1:80*        

  *Lupus anticoagulant (LAC, ratio)*        *0.92*        *\<1.30*

  *Anti-cardiolipin IgG antibodies*         *0.0*         *\<15 GPL/ml*

  *Anti-cardiolipin IgM antibodies*         *0.0*         *\<15 MPL/ml*

  *Anti-β2 glycoprotein 1 IgG antibodies*   *0.0*         *\<15 UA/ml*

  *Anti-β2 glycoprotein 1 IgM antibodies*   *0.1*         *\<15 UA/ml*
  -----------------------------------------------------------------------
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